Zyngenia Inc. is dedicated to the development of innovative biotherapeutics that target multiple biological pathways simultaneously, addressing the complexities of various diseases. The company specializes in smartly engineered monoclonal antibody-based therapeutics, which allow for the creation of new biologic activities. This approach aims to meet unmet medical needs in the treatment of conditions such as cancer, inflammation, and autoimmune disorders. By focusing on multi-specific antibody therapeutics, Zyngenia seeks to enhance disease intervention while maintaining the cost and development efficiency typically associated with a single biologic agent.

The company's technology portfolio includes bi-specific and tri-specific antibodies, such as Bi-Specific Anti-Her2, Bi-Specific Anti-TNFα/ANG2, and Bi-Specific TRAIL Receptor-2, which are designed to target specific pathways involved in disease progression. This multi-targeting strategy not only improves therapeutic efficacy but also aims to provide comprehensive treatment options for patients. Zyngenia's commitment to advancing biotherapeutics is underscored by its ongoing research and development efforts, as well as its collaborations with leading experts in the life sciences field.

United States

Zyngenia is a biotechnology company that develops highly specific, single molecule biotherapeutics targeting multiple physiologic pathways to treat complex diseases like cancer and inflammation.

Zyngenia

Company Details